Associated Papers
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small cell lung cancer.
Wang Z et al.
Biorxiv : the Preprint Server for Biology, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients.
Abdelmaksoud-Dammak R et al.
Molecular Biology Reports, 2026
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Hernandez S et al.
Lung Cancer (amsterdam, Netherlands), 2026
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.
Rocca A et al.
British Journal of Cancer, 2025
Challenges associated with the treatment of E709K and L858R double mutation in lung adenocarcinoma: A case report and literature review.
Song J et al.
Oncology Letters, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World Study.
Shigematsu L et al.
Thoracic Cancer, 2025
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
Hartner S et al.
Nature Communications, 2025
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.
Miyamura BV et al.
Med (new York, N.y.), 2025
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Park S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.
Mamesaya N et al.
International Journal of Clinical Oncology, 2025
Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients.
Huang Y et al.
Esmo Open, 2025
A universal approach for mutation identification with a DNA probe-enzyme combination platform.
Li B et al.
Analytical Methods : Advancing Methods and Applications, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Julian L et al.
Biorxiv : the Preprint Server for Biology, 2025
Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.
Nguyen HV et al.
Oncology Letters, 2025
Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations.
Quach TD et al.
Cancer Reports (hoboken, N.j.), 2025
Exceptional Response to Immunotherapy-based Treatment in Compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report.
Gianchandani A et al.
Journal of Immunotherapy and Precision Oncology, 2025
Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies.
Heriyanto DS et al.
Narra J, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.
Pagliarini RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
Oh MS et al.
Clinical Lung Cancer, 2025
Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.
Nguyen HB et al.
Practical Laboratory Medicine, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.
Sisoudiya SD et al.
Npj Precision Oncology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Absence of KRAS Mutation as an Indicator of Pancreatic Metastasis Originating From Lung Cancer: A Case Report.
Suzuki S et al.
Cureus, 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Complementary modes of resistance to EGFR TKI in lung adenocarcinoma through MAPK activation and cellular plasticity.
Zatzman M et al.
Biorxiv : the Preprint Server for Biology, 2025
Dual Disruption of DNA Repair by a Novel CHK2 Inhibitor, ART-446, and Olaparib is a Promising Strategy for Triple-Negative Breast Cancer Therapy.
Kang HJ et al.
Biomolecules & Therapeutics, 2025
Molecular Testing for EGFR Mutation in Moroccan NSCLC Patients: CHU Hassan II-Fez Experience.
Boukansa S et al.
International Journal of Surgical Pathology, 2025
Development and validation of machine learning models based on molecular features for estimating the probability of multiple primary lung carcinoma versus intrapulmonary metastasis in patients presenting multiple non-small cell lung cancers.
Liu N et al.
Translational Lung Cancer Research, 2025
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M et al.
Translational Lung Cancer Research, 2025
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort.
Niesner ICC et al.
Journal of Clinical Pathology, 2025
Investigating the frequencies of EGFR mutations and EGFR single nucleotide polymorphisms genotypes and their predictive role in NSCLC patients in Republic of Serbia.
Obradović J et al.
Molecular Biology Reports, 2025
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report.
Tavernari D et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.
Yuejian et al.
Investigational New Drugs, 2025
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer.
Krayim B et al.
Translational Lung Cancer Research, 2025
Real-World Performance of the EasyPGX® Ready Epidermal Growth Factor Receptor Assay for Genomic Testing of Non-Small Cell Lung Cancer Samples.
Schmid MB et al.
Biomedicines, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify® Mutation Profiler.
Pepe F et al.
Oncology and Therapy, 2025